<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; India</title>
	<atom:link href="http://www.tapanray.in/tag/india/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Indian Pharma’s Real Marketing Bottleneck Is Not Talent &#8211; It Is Trust: Why Gen X Must Be Given Strategic Control</title>
		<link>http://www.tapanray.in/indian-pharmas-real-marketing-bottleneck-is-not-talent-it-is-trust-why-gen-x-must-be-given-strategic-control/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharmas-real-marketing-bottleneck-is-not-talent-it-is-trust-why-gen-x-must-be-given-strategic-control</link>
		<comments>http://www.tapanray.in/indian-pharmas-real-marketing-bottleneck-is-not-talent-it-is-trust-why-gen-x-must-be-given-strategic-control/#comments</comments>
		<pubDate>Tue, 06 Jan 2026 11:34:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bottleneck]]></category>
		<category><![CDATA[Gen X]]></category>
		<category><![CDATA[Gen Y]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Talen]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11017</guid>
		<description><![CDATA[Over-managed Gen X marketers, over-relied-upon experience, and why Indian pharma’s marketing speed problem is self-inflicted. Executive Summary: The purpose of this article is to provoke a necessary leadership rethink within Indian pharmaceutical marketing. Indian pharma is not short of talent; &#8230; <a href="http://www.tapanray.in/indian-pharmas-real-marketing-bottleneck-is-not-talent-it-is-trust-why-gen-x-must-be-given-strategic-control/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharmas-real-marketing-bottleneck-is-not-talent-it-is-trust-why-gen-x-must-be-given-strategic-control/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why India Encourages Healthcare Innovation &#8211; but Refuses to Copy the Western IP Model</title>
		<link>http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model</link>
		<comments>http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/#comments</comments>
		<pubDate>Sun, 21 Dec 2025 10:43:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[exclusion]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[incision]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[logic]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[monopoly]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[orthodoxy]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[western]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11013</guid>
		<description><![CDATA[Debates on pharmaceutical innovation often polarize quickly into pro-IP and anti-IP camps. This article deliberately avoids that binary. It examines why India encourages innovation while resisting blind replication of Western IP frameworks—and why that distinction matters for healthcare outcomes. Innovation &#8230; <a href="http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s Healthcare Is Still Not Patient-Friendly &#8211; Why ‘Patient Centricity’ in Pharma Remains a Slogan More Than a System</title>
		<link>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system</link>
		<comments>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/#comments</comments>
		<pubDate>Sun, 23 Nov 2025 14:17:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[friendly]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[not patient]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[slogan]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11004</guid>
		<description><![CDATA[Executive Summary: Despite constant advocacy around “patient centricity,” India’s healthcare ecosystem &#8211; from pharma to hospitals &#8211; continues to show deep structural gaps. Safety failures, unethical marketing practices, opaque pricing, and hospital-level exploitation still undermine patient trust. This article uses illustrative &#8230; <a href="http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>US Biosimilar Overhaul: A Breakthrough Moment or a Strategic Test for Indian Pharma</title>
		<link>http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma</link>
		<comments>http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/#comments</comments>
		<pubDate>Sun, 09 Nov 2025 08:01:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Breakthrough]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[overhaul]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[test]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10996</guid>
		<description><![CDATA[On 31 October 2025, the Economic Times (ET) headline— “US biosimilar norms to keep local drug cos in good health” - quickly became one of the most discussed topics across India’s biopharmaceutical circles. For India, which is transitioning from a global generics’ powerhouse &#8230; <a href="http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>When Pills Betray Trust</title>
		<link>http://www.tapanray.in/when-pills-betray-trust/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-pills-betray-trust</link>
		<comments>http://www.tapanray.in/when-pills-betray-trust/#comments</comments>
		<pubDate>Sun, 02 Nov 2025 07:25:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[betray]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lies]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceuical]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10993</guid>
		<description><![CDATA[Why India’s Drug Quality Crisis Demands a Mindset Reset? A Familiar Headline, a Fading Sense of Shock: It happened again. According to The Economic Times (October 24, 2025), 112 drug samples failed quality tests in September — one even found spurious. If that &#8230; <a href="http://www.tapanray.in/when-pills-betray-trust/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-pills-betray-trust/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beyond the Business Card: What Retirement Truly Gives Back</title>
		<link>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-the-business-card-what-retirement-truly-gives-back</link>
		<comments>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/#comments</comments>
		<pubDate>Sun, 26 Oct 2025 07:30:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Card]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[p0wer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[retirement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10986</guid>
		<description><![CDATA[A thought-provoking LinkedIn post by a highly accomplished veteran of the pharmaceutical industry — long retired, but still as insightful as ever — recently caught my attention. It sparked a series of reflections on an issue that deeply resonates with &#8230; <a href="http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>When Patents, Patients and Prices Collide</title>
		<link>http://www.tapanray.in/when-patents-patients-and-prices-collide/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-patents-patients-and-prices-collide</link>
		<comments>http://www.tapanray.in/when-patents-patients-and-prices-collide/#comments</comments>
		<pubDate>Sun, 19 Oct 2025 12:39:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[atrophy]]></category>
		<category><![CDATA[Collide]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Evrysdi]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[muscular]]></category>
		<category><![CDATA[Natco Pharma]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Risdiplam]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[spinal]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10982</guid>
		<description><![CDATA[Supreme Court Clears Natco to Launch Low-Cost Version of Roche’s Spinal Drug in India: A Judgment That Redefines Access and Innovation in India’s Pharma Landscape. The Supreme Court of India has just recently refused to interfere with the Delhi High &#8230; <a href="http://www.tapanray.in/when-patents-patients-and-prices-collide/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-patents-patients-and-prices-collide/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>When ‘Vikshit Bharat’ Rings Hollow: A Tragedy That Exposes India’s Uneven Progress</title>
		<link>http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress</link>
		<comments>http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/#comments</comments>
		<pubDate>Fri, 10 Oct 2025 11:25:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cough]]></category>
		<category><![CDATA[death]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[hollow]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rings]]></category>
		<category><![CDATA[syrup]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tragedy]]></category>
		<category><![CDATA[Vikshit Bharat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10978</guid>
		<description><![CDATA[India’s vision of Vikshit Bharat promises inclusive growth and modern progress. Yet, when children die from contaminated cough syrup, that dream rings hollow. This article asks the hard question: can a nation truly be “developed” when its weakest citizens still fall victim &#8230; <a href="http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-vikshit-bharat-rings-hollow-a-tragedy-that-exposes-indias-uneven-progress/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma and Climate Change: The Unseen Reckoning</title>
		<link>http://www.tapanray.in/pharma-and-climate-change-the-unseen-reckoning/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-and-climate-change-the-unseen-reckoning</link>
		<comments>http://www.tapanray.in/pharma-and-climate-change-the-unseen-reckoning/#comments</comments>
		<pubDate>Thu, 02 Oct 2025 12:09:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Climate change]]></category>
		<category><![CDATA[Donald]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Pharma CEO]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[UN]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10975</guid>
		<description><![CDATA[When the U.S. President Donald Trump addressed the UN General Assembly in September 2025, his remarks on climate change were strikingly dismissive. While global leaders urged urgent action, Trump doubled down, calling climate concerns “a con job” and questioning the &#8230; <a href="http://www.tapanray.in/pharma-and-climate-change-the-unseen-reckoning/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-and-climate-change-the-unseen-reckoning/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>When Patents Meet Patients: Why India Revoked Novartis’ Vymada Patent</title>
		<link>http://www.tapanray.in/when-patents-meet-patients-why-india-revoked-novartis-vymada-patent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-patents-meet-patients-why-india-revoked-novartis-vymada-patent</link>
		<comments>http://www.tapanray.in/when-patents-meet-patients-why-india-revoked-novartis-vymada-patent/#comments</comments>
		<pubDate>Thu, 18 Sep 2025 12:11:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Entresto]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revoked]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vymada]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10971</guid>
		<description><![CDATA[India’s bold move against Novartis’ blockbuster heart drug patent highlights the country’s uncompromising balance between innovation incentives and affordable access to medicines. The Verdict That Stirred the Industry: On September 12, 2025, the Indian Patent Office revoked Novartis’ patent on Vymada (internationally known &#8230; <a href="http://www.tapanray.in/when-patents-meet-patients-why-india-revoked-novartis-vymada-patent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-patents-meet-patients-why-india-revoked-novartis-vymada-patent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
